-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
-
Summary
-
Inhibikase Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from Q1 2020 to Q1 2024.
- Inhibikase Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending March 31, 2024 was -$3.87M, a 35.2% increase year-over-year.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$18.1M, a 4.23% decline from 2022.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$17.4M, a 21.4% decline from 2021.
- Inhibikase Therapeutics, Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was -$14.3M, a 1166% decline from 2020.
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)